Related Experiment Videos
Treating hypertension and cardiovascular risk: are there trade-offs?
1Division of Epidemiology, School of Public Health, University of Minnesota, Minneapolis 55455.
Insights
Antihypertensive drugs impact blood lipids differently. Alpha-1 inhibitors offer favorable lipid profiles, potentially reducing coronary heart disease risks, unlike thiazides and beta-blockers.
Area of Science:
- Cardiovascular Pharmacology
- Lipid Metabolism
- Pharmacotherapy
Background:
- Antihypertensive agents exhibit varied effects on blood lipid profiles.
- Thiazide diuretics and beta-blockers can negatively impact lipids, potentially counteracting cardiovascular benefits.
- Alpha-1 inhibitors demonstrate a favorable lipid-modifying profile.
Purpose of the Study:
- To compare the lipid effects of different classes of antihypertensive agents.
- To assess the potential impact of these lipid changes on coronary heart disease risk.
- To evaluate the long-term cost-effectiveness considering both blood pressure and lipid effects.
Main Methods:
- Review of existing clinical trial data on antihypertensive agents.
- Analysis of effects on total cholesterol, low-density lipoprotein, high-density lipoprotein (HDL), and triglycerides.
- Estimation of secondary disease outcome costs based on lipid profile alterations.
Main Results:
- Thiazide diuretics increase total cholesterol, LDL, and triglycerides, while slightly decreasing HDL.
- Beta-blockers are linked to increased triglycerides and reduced HDL.
- Alpha-1 inhibitors (prazosin, doxazosin, terazosin) lower total cholesterol, increase HDL, and improve the HDL/total cholesterol ratio.
Conclusions:
- The favorable lipid effects of alpha-1 inhibitors may mitigate concerns associated with other antihypertensives.
- Lipid alterations induced by thiazides and some beta-blockers might offset cardiovascular benefits.
- Long-term treatment costs may be comparable due to the offsetting effects of lipid profiles and secondary costs.
Abstract:
Numerous studies have demonstrated that antihypertensive agents differentially affect blood lipids. Thiazide diuretics increase total cholesterol, low-density lipoprotein, and triglycerides and cause a slight reduction in high-density lipoprotein (HDL). Most beta-blockers are associated with large increases in triglycerides and substantial reductions in HDL. Conversely, alpha 1-inhibitors, such as prazosin, doxazosin, and terazosin, lower total cholesterol, increases HDL, and favorably alter the HDL/total cholesterol ratio. Results of major clinical trials have demonstrated that lowering total cholesterol or low-density lipoprotein and increasing HDL reduces the risk of coronary heart disease. Therefore concerns have increased that the lipid effects of thiazides and some beta-blockers may totally or partly negate the beneficial reduction on coronary heart disease afforded by blood pressure reduction. Trial data can be used to estimate the potential secondary costs of disease outcomes that would be associated with lipid differences. Because there are presumably no secondary costs with alpha 1-inhibitors as a result of their favorable effects on lipids and because there are substantial secondary costs associated with thiazides, the cost of long-term treatment would be similar for the two agents.